The International Prognostic Scoring System for Waldenström's macroglobulinemia is applicable in patients treated with rituximab-based regimens

Haematologica

Volumn 93, Issue 9, 2008, Pages 1420-1422

  Dimopoulos, Meletios Athanasios ^a   Kastritis, Efstathios ^a   Delimpassi, Sossana ^b   Zomas, Athanasios ^c   Kyrtsonis, Marie Christine ^d   Zervas, Konstantinos ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Evangelismos Hospital   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Cause specific survival; High risk; Prognosis; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN M; MITOXANTRONE; RITUXIMAB;

AGING; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPOALBUMINEMIA; LETTER; MULTIPLE CYCLE TREATMENT; SCORING SYSTEM; SPLENOMEGALY; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PROGNOSIS; SOCIETIES, MEDICAL; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

EID: 50849133905     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12846     Document Type: Letter

References (12)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol 2005;23:1564-77.
2. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000;96:852-8.
3. Gobbi PG, Bettini R, Montecucco C, Cavanna L, Morandi S, Pieresca C, et al. Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994;83:2939-45.
4. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001;115:575-82.
5. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, et al. Prognostic factors in symptomatic Waldenström's macroglobulinemia. Semin Oncol 2003;30:211-5.
6. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenström macroglobulinaemia. Br J Haematol 2006;133:158-64.
7. Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-8.
8. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:116-20.
9. th International Workshop on Waldenstrom's Macroglobulinemia 25 30 June 2007 Kos Island, Greece. Haematologica 2007;92(6 suppl 2):1-229.
10. Dimopoulos MA, Anagnostopoulos A, Zervas C, Kyrtsonis MC, Zomas A, Bourantas C, et al. Predictive factors for response to rituximab in Waldenström's macroglobulinemia. Clin Lymphoma 2005;5:270-2.
11. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-9.
12. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood 2006;107:3442-6.